' Jury Still Out ' on Adjuvant Therapy in Kidney Cancer ' Jury Still Out ' on Adjuvant Therapy in Kidney Cancer

Although sunitinib improves disease-free survival in high-risk resected renal cancer and adverse events are manageable, many patients discontinue therapy, and its role is a matter of debate, say experts.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news